Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan

AimsA novel tool for the evaluation of left ventricular (LV) systo-diastolic function through echo-derived haemodynamic forces (HDFs) has been recently proposed. The present study aimed to assess the predictive value of HDFs on (i) 6 month treatment response to sacubitril/valsartan in heart failure with reduced ejection fraction (HFrEF) patients and (ii) cardiovascular events. Methods and resultsEighty-nine consecutive HFrEF patients [70% males, 65 & PLUSMN; 9 years, LV ejection fraction (LVEF) 27 & PLUSMN; 7%] initiating sacubitril/valsartan underwent clinical, laboratory, ultrasound and cardiopulmonary exercise testing evaluations. Patients experiencing no adverse events and showing & GE;50% reduction in plasma N-terminal pro-B-type natriuretic peptide and/or & GE;10% LVEF increase over 6 months were considered responders. Patients were followed up for the composite endpoint of HF-related hospitalisation, atrial fibrillation and cardiovascular death. Forty-five (51%) patients were responders. Among baseline variables, only HDF-derived whole cardiac cycle LV strength (wLVS) was higher in responders (4.4 & PLUSMN; 1.3 vs. 3.6 & PLUSMN; 1.2; p = 0.01). wLVS was also the only independent predictor of sacubitril/valsartan response at multivariable logistic regression analysis [odds ratio 1.36; 95% confidence interval (CI) 1.10-1.67], with good accuracy at receiver operating characteristic (ROC) analysis [optimal cutpoint: & GE;3.7%; area under the curve (AUC) = 0.736]. During a 33 month (23-41) median follow-up, a wLVS increase after 6 months (& UDelta;wLVS) showed a high discrimination ability at time-dependent ROC analysis (optimal cut-off: & GE;0.5%; AUC = 0.811), stratified prognosis (log-rank p < 0.0001) and remained an independent predictor for the composite endpoint (hazard ratio 0.76; 95% CI 0.61-0.95; p < 0.01), after adjusting for clinical and instrumental variables. ConclusionsHDF analysis predicts sacubitril/valsartan response and might optimise decision-making in HFrEF patients.